Author:
Naranjo Antonio,Cáceres Laura,Hernández-Beriaín José Ángel,Francisco Félix,Ojeda Soledad,Talaverano Sigrid,Nóvoa-Medina Javier,Martín José Adán,Delgado Esmeralda,Trujillo Elisa,Álvarez Fátima,Magdalena Laura,Rodríguez-Lozano Carlos
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference16 articles.
1. Smolen JS, Aletaha D, Bijlsma JW, T2T Expert Committee et al (2011) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 70:1519
2. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol 66:775–782
3. Pyne L, Bykerk VP, Boire G et al (2012) Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. J Rheumatol 39:2081–2087
4. Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B (2013) Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 52:391–399
5. Pincus T, Castrejón I (2013) Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis 71(Suppl 1):S33–S40
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献